Here we treated different breast cancer cell lines and the non-tumorigenic MCF-10A cells with the FDA-approved HDAC inhibitor valproate (VPA) or suberoylanilide hydroxamic acid (SAHA; Vorinostat), which are currently tested in clinical trials for breast cancer treatment [6–8]. This evidence concerns the gene HDAC9 and breast carcinoma.